Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Celiac Disease Enzyme Therapy Market: Gluten Peptide Degradation Demand, Prolyl Endopeptidase Platform Growth, and Inadvertent Gluten Exposure Protection Adoption to Drive Strong Market Expansion Through 2035

The global Celiac Disease Enzyme Therapy Market is projected to expand at a strong CAGR of 20.5% through 2035, driven by sustained clinical demand for oral gluten peptide degradation therapy, growing development of prolyl endopeptidase and multi-enzyme combination platforms, and continued positioning of enzyme therapy as protection against inadvertent gluten exposure rather than a replacement for the gluten-free diet. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises TAK-062 and latiglutenase as leading clinical-stage candidates, alongside AN-PEP-based therapies and other engineered gluten-degrading enzyme programs, with no celiac disease enzyme therapy yet commercially approved for this specific indication.

The market’s strong 20.5% CAGR reflects growing clinical and patient recognition that the gluten-free diet, while foundational to celiac disease management, does not fully protect against inadvertent gluten exposure from cross-contamination and hidden dietary sources, generating structured demand from gastroenterology clinics and celiac disease specialty centers well above discretionary specialty pharmaceutical demand growth. Enzyme therapy candidates including TAK-062, an engineered gluten-degrading enzyme, and latiglutenase, a combination of two recombinant gluten-specific proteases, continue to advance through clinical development with the specific goal of degrading residual dietary gluten peptides in the gastrointestinal tract before they can trigger the autoimmune inflammatory response underlying celiac disease. Coverage extending across multiple enzyme types, origins, and treatment objectives underscores the breadth of clinical and manufacturing infrastructure now supporting this pre-commercial but clinically important category.

Executive Snapshot

How does gluten peptide degradation demand drive the celiac disease enzyme therapy market?
Gastroenterology clinics continue to evaluate enzyme therapy candidates designed to degrade immunogenic gluten peptides in the gastrointestinal tract before they can trigger autoimmune inflammation, establishing this mechanism as the central therapeutic rationale for the category. As clinical evidence continues to accumulate, procurement associated with gluten peptide degradation therapy is expected to remain the dominant category through the forecast period.

What role does prolyl endopeptidase platform growth play in market expansion?
Biopharmaceutical developers continue to advance prolyl endopeptidase and related protease enzyme platforms, including AN-PEP-based therapies, sustaining structured demand from developers pursuing this enzyme class given its specific capacity to cleave the proline-rich peptide sequences characteristic of immunogenic gluten fragments.

How does inadvertent gluten exposure protection adoption sustain market growth?
Treatment centers increasingly position enzyme therapy as a protective measure against inadvertent gluten exposure from cross-contamination and hidden dietary sources rather than a replacement for the gluten-free diet, sustaining structured demand from patients and clinicians pursuing this complementary rather than substitutive treatment approach.

What is driving demand for celiac disease enzyme therapy in refractory and non-responsive disease applications?
Developers pursuing enzyme therapy candidates for patients with persistent intestinal damage despite strict dietary adherence continue to extend this therapeutic approach to refractory celiac disease populations, generating incremental demand among gastroenterology specialists pursuing treatment options for this difficult-to-manage patient subgroup.

How does multi-enzyme combination therapy demand sustain the market?
Biopharmaceutical developers continue to advance combination enzyme cocktails incorporating multiple protease types with complementary gluten-degrading activity, sustaining structured demand from developers pursuing more comprehensive dietary gluten degradation relative to single-enzyme approaches.

Which celiac disease enzyme therapy market segments are growing fastest?
The fastest-growing segments include multi-enzyme combination formulations, engineered and recombinant enzyme platforms, refractory celiac disease applications, and next-generation enzyme cocktails designed for broader dietary gluten degradation coverage.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Celiac Disease Enzyme Therapy Market

  • TAK-062 and latiglutenase sustaining the leading share of current clinical development activity: These two lead candidates continue to represent the most clinically advanced enzyme therapy programs within the current celiac disease treatment pipeline.
  • Prolyl endopeptidase sustaining the dominant enzyme type across the current clinical pipeline: This enzyme class continues to anchor the majority of current celiac disease enzyme therapy development given its established mechanism against proline-rich gluten peptides.
  • Inadvertent gluten exposure protection sustaining the primary current positioning relative to gluten-free diet replacement: This complementary treatment framing continues to shape clinical development strategy and anticipated commercial messaging across the category.
  • Recombinant and engineered enzyme platforms sustaining structured demand above naturally derived enzyme sources: These manufactured enzyme approaches continue to attract developer investment pursuing improved consistency and specificity relative to natural enzyme sources.
  • Multi-enzyme combination formulations sustaining structured demand growth above single-enzyme approaches: Combined protease activity continues to attract developer interest pursuing more comprehensive gluten peptide degradation coverage.
  • Clinical-stage development sustaining the entirety of current market activity ahead of first commercial approval: The absence of a currently approved celiac disease-specific enzyme therapy continues to concentrate all market activity within clinical development.

Market Segmentation: Celiac Disease Enzyme Therapy Market

By Product Type
  • TAK-062
  • Latiglutenase (ZMGX003)
  • AN-PEP-based therapies
  • Glutenase combinations
  • Engineered gluten-degrading enzymes
  • Others
By Enzyme Type
  • Prolyl Endopeptidase (PEP)
  • Glutenase
  • Endopeptidase
  • Exopeptidase
  • Cysteine Protease
  • Microbial-Derived Proteases
  • Recombinant Proteases
  • Multi-Enzyme Combinations
By Disease Type
  • Classical Celiac Disease
  • Non-Classical Celiac Disease
  • Potential / At-Risk Celiac Disease
  • Refractory Celiac Disease
  • Seropositive Celiac Disease
  • Newly Diagnosed Celiac Disease
By Formulation
  • Immediate-Release
  • Enteric-Coated
  • Gastro-Resistant
  • pH-Optimized
  • Delayed-Release
  • Enzyme-Stabilized
  • Multi-Enzyme Formulation
  • Liquid Enzyme Formulation
By Disease Stage
  • Mild
  • Moderate
  • Moderate-to-Severe
  • Severe
  • Refractory / Treatment-Resistant
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Gastroenterology Clinics
  • Specialty Clinics
  • Hospitals
  • Academic Medical Centers
  • Celiac Disease Centers
  • Research Institutes
  • Specialty Pharmacies
  • Homecare
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Celiac Disease Enzyme Therapy Market

  1. Sustained patient and clinical recognition of gluten-free diet limitations driving enzyme therapy development investment: Protection against inadvertent exposure continues to support structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing developer investment in prolyl endopeptidase and related protease platforms supporting continued clinical advancement: This enzyme class continues to attract structured research investment given its established mechanism against gluten-derived peptides.
  3. Continued clinical positioning as a complementary rather than substitutive treatment supporting broad patient acceptance: This treatment framing continues to support structured demand from patients maintaining dietary management alongside enzyme therapy.
  4. Sustained clinical interest in refractory celiac disease broadening the addressable patient population: This difficult-to-manage patient subgroup continues to generate incremental developer interest in enzyme therapy applications.
  5. Growing formulation science investment in multi-enzyme combinations supporting more comprehensive gluten degradation: Combined protease activity continues to attract structured developer investment pursuing improved therapeutic coverage.
  6. Maturing Phase II and Phase III pipeline supporting an approaching wave of regulatory submissions: Continued clinical advancement across multiple lead candidates continues to focus treatment center and payer attention on the category’s next phase of development.

Regional Outlook: Celiac Disease Enzyme Therapy Market

  • North America: The United States accounts for the largest share of regional clinical trial activity, supported by extensive gastroenterology and celiac disease specialty center infrastructure and leading biopharmaceutical developer presence.
  • Europe: Germany, Italy, and the United Kingdom anchor regional clinical trial activity, supported by high celiac disease prevalence and growing specialized gastroenterology center capacity; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent growing regional markets as celiac disease diagnosis rates increase and regional biopharmaceutical developers expand participation in enzyme therapy clinical development.
  • Latin America: Brazil and Argentina represent an emerging regional demand base as specialized gastroenterology centers begin to participate in celiac disease enzyme therapy clinical trials.

Competitive Landscape: Celiac Disease Enzyme Therapy Market

Key Players
Takeda Pharmaceutical Company Limited, ImmunogenX, Inc., DSM-Firmenich AG, Amneal Pharmaceuticals, Inc., Zedira GmbH

  • Takeda Pharmaceutical Company Limited [March 2026] — confirmed continued clinical development of TAK-062, its engineered gluten-degrading enzyme candidate, with the company noting sustained investigator interest in its potential to protect against inadvertent gluten exposure.
  • ImmunogenX, Inc. [December 2025] — reported continued Phase II clinical development of latiglutenase, with the company noting sustained patient interest in its combination protease mechanism for gluten peptide degradation.
  • Zedira GmbH [September 2025] — confirmed continued research investment in enzyme-based celiac disease therapeutic approaches, with the company reporting structured interest in expanding its protease platform for gastrointestinal gluten degradation applications.

Consultant POV

The Celiac Disease Enzyme Therapy Market’s strong 20.5% CAGR outlook through 2035 is anchored in sustained gluten peptide degradation demand, growing prolyl endopeptidase platform activity, and continued inadvertent gluten exposure protection adoption. Sustained clinical investment from companies including Takeda Pharmaceutical Company Limited, ImmunogenX, Inc., and Zedira GmbH confirms the Celiac Disease Enzyme Therapy Market will sustain strong growth through 2035 as leading candidates progress through late-stage clinical development.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report